PDF) Effectiveness of Risk Evaluation and Mitigation Strategies ...
PDF) Effectiveness of Risk Evaluation and Mitigation Strategies ... | revlimid rems form

Seven Things You Probably Didn’t Know About Revlimid Rems Form | Revlimid Rems Form

Posted on

Celgene Corporation (CELG) today appear that abstracts from a ample ambit of aboriginal and backward date studies evaluating Celgene investigational agents and investigational uses of marketed articles will be presented at the 23rd European Hematology Association (EHA) annual affair in Stockholm, Sweden, from June 14-17, 2018.

PDF) Effectiveness of Risk Evaluation and Mitigation Strategies ..
PDF) Effectiveness of Risk Evaluation and Mitigation Strategies .. | revlimid rems form

“We are appreciative to be administration new and adapted abstracts about our avant-garde hematological therapies at EHA 2018, which added our compassionate of claret cancers and added blood-related diseases and acquiesce us to abide to accept a above appulse on the lives of patients,” said Nadim Ahmed, President, Hematology & Oncology Franchise. “The abstracts presented at EHA accentuate the important role of immunomodulatory drugs at assorted stages of assorted myeloma, as able-bodied as allegorize our advancing assignment in developing avant-garde assay options, such as our erythroid maturation abettor and CAR T corpuscle therapies, for patients with activity advancing claret disorders and cancers.”

At EHA this year, abstracts will be presented on Revlimid in both Anew Diagnosed Assorted Myeloma and as aliment treatment, and Pomalyst aggregate regimens afterward Revlimid use, including new abstracts from the Phase III OPTIMISMM balloon in the relapsed/refractory setting. After-effects from the Phase III RELEVANCE abstraction of lenalidomide added rituximab (R2) against rituximab added chemotherapy, followed by rituximab, in ahead basic follicular lymphoma patients will be featured during the meeting’s Presidential Symposium. Abstracts will additionally be presented on Celgene’s CAR T corpuscle therapies, including adapted allegation on bb2121 in assorted myeloma and cardinal analytic abstracts on JCAR017 in lymphoma. Additionally, 2-year assurance and ability abstracts on luspatercept, an investigational compound, in beta-thalassemia will be presented.

Abstract #S138; Oral; Friday, June 15, 12.30 – 12.45, Room A8. bb2121 anti-BCMA CAR T corpuscle assay in patients with relapsed/refractory assorted myeloma: adapted after-effects from a multicenter Phase I study. (Raje)

Abstract #S800; Oral; Saturday, June 16, 11:45 – 12:00, Room A1. Adapted assurance and connected appellation analytic outcomes in TRANSCEND NHL 001, cardinal balloon of lisocabtagene maraleucel (JCAR017) in r/r advancing NHL (Abramson)

Abstract #PS1429; Poster Presentation; Saturday, June 16, 17:30 – 19:00. Cost allegory of assay strategies afterward admission with Rd against VMP added daratumumab in anew diagnosed patients disqualified for ASCT. (Jackson)

Abstract #PF570; Poster Presentation; Friday, June 15, 17:30 – 19:00. Development of a predictive archetypal of assorted myeloma (MM) accommodating outcomes based on assay (tx) sequencing application abstracts from The Connect® MM Accommodating Registry. (Jagannath)

Abstract #S847; Oral; Saturday, June 16, 16:00 – 16:15, Room A1. OPTIMISMM: Phase III balloon of pomalidomide, bortezomib, and low‐dose dexamethasone vs bortezomib and low-dose dexamethasone in lenalidomide-exposed patients with relapsed or adverse assorted myeloma. (Richardson)

Abstract #PF567; Poster Presentation; Friday, June 15, 17:30 – 19:00. Assurance and ability of pomalidomide added low-dose dexamethasone anon afterward lenalidomide-based assay abortion in patients with relapsed and/or adverse assorted myeloma. (Siegel)

Abstract #PS1292; Poster Presentation; Saturday, June 16, 17:30 – 19:00. Pomalidomide added low-dose dexamethasone added daratumumab in patients with relapsed and/or adverse assorted myeloma afterwards lenalidomide-based assay failure. (Siegel)

Abstract #PF576; Poster Presentation; Friday, June 15, 17:30 – 19:00. Assurance outcomes in patients with relapsed/refractory assorted myeloma (RRMM) advised with lenalidomide for ≤ 24 months vs > 24 months in a European post-approval assurance abstraction (EU Pass). (Semenzato)

Abstract #PF562; Poster Presentation; Friday, June 15, 17:30 – 19:00. Aliment afterwards lenalidomide, bortezomib, and dexamethasone consecration and displace in patients with anew diagnosed assorted myeloma and high-risk cytogenetics: an added medical almanac analysis. (Fonseca)

Acute Myeloid Leukemia

Abstract #PS980; Poster Presentation; Saturday, June 16, 17:30 – 19:00. Continuing enasidenib assay for patients with mutant-IDH2 relapsed/refractory astute myeloid leukemia (r/r AML) with abiding ache may aftereffect in bigger responses and adaptation over time. (Stein)

Abstract #S1562; Oral; Sunday, June 17, 08:30 – 08:45, Victoria Hall. Mutant IDH (MIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with astute myeloid leukemia (AML). (DiNardo)

Lymphoma

Abstract #S154; Oral; Friday, June 15, 17:00 – 17:15, Room A1. RELEVANCE: Phase III ability and assurance abstraction of lenalidomide added rituximab (R2) against rituximab added chemotherapy, followed by rituximab, in ahead basic follicular lymphoma. (Morschhauser)

NDC 12-12 Thalomid Thalidomide - revlimid rems form
NDC 12-12 Thalomid Thalidomide – revlimid rems form | revlimid rems form

Beta-Thalassemia

Abstract #S844; Oral; Saturday, June 16, 12:00 – 12:15, Room K2. Improvements in hemoglobin, affection of life, and six-minute-walk ambit in adults with β-thalassemia advised with luspatercept: abiding Phase II study. (Piga)

The assurance and ability of the agents and/or uses beneath analysis accept not been established. There is no agreement that the agents will accept bloom ascendancy approval or become commercially accessible in any country for the uses actuality investigated.

A complete advertisement of abstracts can be begin on the EHA Learning Center Web armpit at https://learningcenter.ehaweb.org/eha.

About Celgene’s Immunomodulatory Drugs

Immunomodulatory Drugs (IMiDs®) are Celgene’s proprietary baby molecule, orally accessible compounds for the assay of some claret cancers. IMiDs® are the foundation of assorted myeloma treatment, apprenticed by the accurate adaptation allowances above curve of therapy. Their apparatus of activity is able-bodied authentic and offers the aggregate of arresting bump cells, aesthetic the allowed system, and synergizing with added classes of treatment. With REVLIMID® (lenalidomide) and POMALYST®/IMNOVID® (pomalidomide), Celgene has a portfolio of avant-garde medicines that accept helped transform the assay of assorted myeloma, accouterment patients best ache ascendancy at every date of the ache from anew diagnosed to backsliding adverse assorted myeloma.

About REVLIMID

REVLIMID in aggregate with dexamethasone (dex) is adumbrated for the assay of patients with assorted myeloma (MM)

REVLIMID is adumbrated as aliment assay in patients with MM afterward autologous hematopoietic axis corpuscle transplantation (auto-HSCT)

REVLIMID is adumbrated for the assay of patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a abatement 5q cytogenetic aberancy with or afterwards added cytogenetic abnormalities

REVLIMID is adumbrated for the assay of patients with crimson corpuscle lymphoma (MCL) whose ache has relapsed or progressed afterwards two above-mentioned therapies, one of which included bortezomib

REVLIMID is not adumbrated and is not recommended for the assay of patients with abiding lymphocytic leukemia (CLL) alfresco of controlled analytic trials

Important Assurance Admonition

Embryo-Fetal Toxicity

Admonition about the REVLIMID REMS affairs is accessible at www.celgeneriskmanagement.com or by calling the manufacturer’s toll-free cardinal 1-888-423-5436.

Hematologic Toxicity (Neutropenia and Thrombocytopenia)

THALOMID® (thalidomide) Patient Prescription Form - revlimid rems form
THALOMID® (thalidomide) Patient Prescription Form – revlimid rems form | revlimid rems form

 

Venous and Arterial Thromboemism

CONTRAINDICATIONS

Pregnancy: REVLIMID can annual fetal abuse aback administered to a abundant changeable and is contraindicated in females who are pregnant. If this biologic is acclimated during abundance or if the accommodating becomes abundant while demography this drug, the accommodating should be acquainted of the abeyant accident to the fetus

Severe Hypersensitivity Reactions: REVLIMID is contraindicated in patients who accept approved astringent hypersensitivity (e.g., angioedema, Stevens-Johnson syndrome, baneful epidermal necrolysis) to lenalidomide

WARNINGS AND PRECAUTIONS

Embryo-Fetal Toxicity: See Boxed WARNINGS

REVLIMID REMS Program: See Boxed WARNINGS: Prescribers and pharmacies charge be certified with the REVLIMID REMS affairs by enrolling and acknowledging with the REMS requirements; pharmacies charge alone allocate to patients who are accustomed to accept REVLIMID. Patients charge assurance a Patient-Physician Agreement Form and accede with REMS requirements; changeable patients of changeable abeyant who are not abundant charge accede with the abundance testing and contraception requirements and males charge accede with contraception requirements

Hematologic Toxicity: REVLIMID can annual cogent neutropenia and thrombocytopenia. Monitor patients with neutropenia for signs of infection. Admonish patients to beam for bleeding or bruising, abnormally with use of accessory medications that may access accident of bleeding. MM: Patients demography REVLIMID/dex or REVLIMID as aliment assay should accept their complete claret counts (CBC) adjourned every 7 canicule for the aboriginal 2 cycles, on canicule 1 and 15 of aeon 3, and every 28 canicule thereafter. MDS: Patients on assay for del 5q MDS should accept their complete claret counts monitored annual for the aboriginal 8 weeks of assay and at atomic annual thereafter. Patients may crave dosage abeyance and/or dosage reduction. Amuse see the Black Box WARNINGS for added information. MCL: Patients demography REVLIMID for MCL should accept their CBCs monitored annual for the aboriginal aeon (28 days), every 2 weeks during cycles 2-4, and again annual thereafter. Patients may crave dosage abeyance and/or dosage reduction

Venous and Arterial Thromboemism: See Boxed WARNINGS: Venous thromboemic contest (DVT and PE) and arterial thromboses (MI and CVA) are added in patients advised with REVLIMID. Patients with accepted accident factors, including above-mentioned thrombosis, may be at greater accident and accomplishments should be taken to try to abbreviate all adjustable factors (e.g., hyperlipidemia, hypertension, smoking). Thromboprophylaxis is recommended and the dieting should be based on patient’s basal risks. ESAs and estrogens may added access the accident of occlusion and their use should be based on a benefit-risk decision

Increased Bloodshed in Patients with CLL: In a analytic balloon in the first-line assay of patients with CLL, audible abettor REVLIMID assay added the accident of afterlife as compared to audible abettor chlorambucil. Austere adverse cardiovascular reactions, including atrial fibrillation, myocardial infarction, and cardiac failure, occurred added frequently in the REVLIMID arm. REVLIMID is not adumbrated and not recommended for use in CLL alfresco of controlled analytic trials

Second Primary Malignancies (SPM): In analytic trials in patients with MM accepting REVLIMID, an access of hematologic added solid bump SPM, conspicuously AML and MDS, accept been observed. Monitor patients for the development of SPM. Booty into annual both the abeyant annual of REVLIMID and accident of SPM aback because treatment

Increased Bloodshed with Pembrolizumab: In analytic trials in patients with assorted myeloma, the accession of pembrolizumab to a thalidomide alternation added dexamethasone resulted in added mortality. Assay of patients with assorted myeloma with a PD-1 or PD-L1 blocking antibiotic in aggregate with a thalidomide alternation added dexamethasone is not recommended alfresco of controlled analytic trials

Hepatotoxicity: Hepatic failure, including baleful cases, has occurred in patients advised with REVLIMID/dex. Pre-existing viral alarmist disease, animated baseline alarmist enzymes, and accessory medications may be accident factors. Monitor alarmist enzymes periodically. Stop REVLIMID aloft acclivity of alarmist enzymes. Afterwards acknowledgment to baseline values, assay at a lower dosage may be considered

Severe Cutaneous Reactions Including Hypersensitivity Reactions: Angioedema and astringent cutaneous reactions including Stevens-Johnson affection (SJS), baneful epidermal necrolysis (TEN), and biologic acknowledgment with eosinophilia and systemic affection (DRESS) accept been reported. DRESS may present with a cutaneous acknowledgment (such as rash, or exfoliative dermatitis), eosinophilia, fever, and/or lymphadenopathy with systemic complications such as hepatitis, nephritis, pneumonitis, myocarditis, and/or pericarditis. These contest can be fatal. Patients with a above-mentioned history of Grade 4 adventurous associated with thalidomide assay should not accept REVLIMID. REVLIMID abeyance or cessation should be advised for Grade 2-3 bark rash. REVLIMID charge be discontinued for angioedema, Grade 4 rash, exfoliative or bullous rash, or if SJS, TEN, or DRESS is doubtable and should not be resumed afterward cessation for these reactions

Tumor Lysis Affection (TLS): Fatal instances of TLS accept been appear during assay with lenalidomide. The patients at accident of TLS are those with aerial bump accountability above-mentioned to treatment. These patients should be monitored carefully and adapted precautions taken

PDF) Assessment of Risk Evaluation and Mitigation Strategies in ..
PDF) Assessment of Risk Evaluation and Mitigation Strategies in .. | revlimid rems form

Tumor Blaze Acknowledgment (TFR): TFR has occurred during investigational use of lenalidomide for CLL and lymphoma. Ecology and appraisal for TFR is recommended in patients with MCL. Bump blaze may actor the progression of ache (PD). In patients with Grade 3 or 4 TFR, it is recommended to abjure assay with REVLIMID until TFR resolves to ≤Grade 1. REVLIMID may be connected in patients with Grade 1 and 2 TFR afterwards abeyance or modification, at the physician’s discretion

Impaired Axis Corpuscle Mobilization: A abatement in the cardinal of CD34 beef calm afterwards assay ( > 4 cycles) with REVLIMID has been reported. Consider aboriginal barometer to displace centermost to optimize timing of the axis corpuscle collection

Thyroid Disorders: Both hypothyroidism and hyperthyroidism accept been reported. Measure thyroid activity afore alpha of REVLIMID assay and during therapy

Early Bloodshed in Patients with MCL: In accession MCL study, there was an access in aboriginal deaths (within 20 weeks), 12.9% in the REVLIMID arm against 7.1% in the ascendancy arm. Accident factors for aboriginal deaths accommodate aerial bump burden, MIPI account at diagnosis, and aerial WBC at baseline (≥10 x 109/L)

ADVERSE REACTIONS

Multiple Myeloma

Myelodysplastic Syndromes

Mantle Corpuscle Lymphoma

DRUG INTERACTIONS

Periodic ecology of digoxin claret levels is recommended due to added Cmax and AUC with accessory REVLIMID therapy. Patients demography accessory therapies such as erythropoietin aesthetic agents or estrogen absolute therapies may accept an added accident of thrombosis. It is not accepted whether there is an alternation amid dex and warfarin. Aing ecology of PT and INR is recommended in patients with MM demography accessory warfarin

USE IN SPECIFIC POPULATIONS

Please see full Prescribing Information, including Boxed WARNINGS.

About IMNOVID

IMNOVID is a thalidomide alternation indicated, in aggregate with dexamethasone, for patients with assorted myeloma who accept accustomed at atomic two above-mentioned therapies including lenalidomide and a proteasome inhibitor and accept approved ache progression on or aural 60 canicule of achievement of the aftermost therapy.

Important Assurance Admonition

WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL THROMBOEMBOLISM

Excess Costs Briefing Paper FINAL* 12 12 12 - revlimid rems form
Excess Costs Briefing Paper FINAL* 12 12 12 – revlimid rems form | revlimid rems form

 

Embryo-Fetal Toxicity

IMNOVID is alone accessible through a belted administration affairs alleged POMALYST REMS.

Venous and Arterial Thromboemism

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

Nearly all patients advised with IMNOVID low-dose dex accomplished at atomic one adverse acknowledgment (99%). The best accepted adverse reactions (≥15%) included neutropenia (51.3%), fatigue and asthenia (46.7%), aerial respiratory amplitude infection (31%), thrombocytopenia (29.7%), agitation (26.7%), dyspnea (25.3%), diarrhea (22%), ache (21.7%), aback affliction (19.7%), ahem (20%), pneumonia (19.3%), cartilage affliction (18%), edema borderline (17.3%), borderline neuropathy (17.3%), beef spasms (15.3%), and abhorrence (15%). Grade 3 or 4 adverse reactions (≥15%) included neutropenia (48.3%), thrombocytopenia (22%), and pneumonia (15.7%).

DRUG INTERACTIONS

Avoid accessory use of IMNOVID with able inhibitors of CYP1A2. Consider another treatments. If a able CYP1A2 inhibitor charge be used, abate IMNOVID dosage by 50%.

USE IN SPECIFIC POPULATIONS

Please see full Prescribing Information, including Boxed WARNINGS.

About IDHIFA

IDHIFA (enasidenib) is adumbrated for the assay of developed patients with relapsed or adverse astute myeloid leukemia with an isocitrate dehydrogenase-2 alteration as detected by an FDA-approved test.

Important Assurance Admonition

WARNING: DIFFERENTIATION SYNDROME

REVLIMID is only available through a restricted distribution program ..
REVLIMID is only available through a restricted distribution program .. | revlimid rems form

Patients advised with IDHIFA accept accomplished affection of adverse syndrome, which can be baleful if not treated. Affection may accommodate fever, dyspnea, astute respiratory distress, pulmonary infiltrates, pleural or pericardial effusions, accelerated weight accretion or borderline edema, lymphadenopathy, cartilage pain, and hepatic, renal, or multi-organ dysfunction. If adverse affection is suspected, admit corticosteroid assay and hemodynamic ecology until evidence resolution.

WARNINGS AND PRECAUTIONS

Differentiation Syndrome: See Boxed WARNING. In the analytic trial, 14% of patients advised with IDHIFA accomplished adverse syndrome. Adverse affection has been empiric with and afterwards accessory hyperleukocytosis, as aboriginal as 10 canicule and at up to 5 months afterwards IDHIFA initiation. If adverse affection is suspected, admit systemic corticosteroids and hemodynamic ecology until improvement. Taper corticosteroids alone afterwards resolution of symptoms. Adverse affection affection may recur with abortive cessation of corticosteroids. If astringent pulmonary affection astute intubation or chase abutment and/or renal dysfunction abide for added than 48 hours afterwards admission of corticosteroids, arrest IDHIFA until signs and affection are no best severe. Hospitalization for aing ascertainment and ecology of patients with pulmonary and/or renal appearance is recommended.

Embryo-Fetal Toxicity: Based on beastly embryo-fetal toxicity studies, IDHIFA can annual embryo-fetal abuse aback administered to a abundant woman. Admonish females of changeable abeyant and males with changeable ally of changeable abeyant to use able contraception during assay with IDHIFA and for at atomic 1 ages afterwards the aftermost dose. Abundant women, patients acceptable abundant while accepting IDHIFA, or macho patients with abundant changeable ally should be acquainted of the abeyant accident to the fetus.

ADVERSE REACTIONS

LACTATION

Many drugs are excreted in beastly milk and because of the abeyant for adverse reactions in fed infants, admonish women not to feed during assay with IDHIFA and for at atomic 1 ages afterwards the aftermost dose.

Please see abounding Prescribing Information, including Boxed WARNING

About Luspatercept

Luspatercept is a adapted activin receptor blazon IIB admixture protein that acts as a ligand allurement for associates in the transforming advance factor-beta superfamily complex in the backward stages of erythropoiesis (red claret corpuscle production). Luspatercept regulates late-stage corpuscle (red claret cell) forerunner corpuscle adverse and maturation. This apparatus of activity is audible from that of erythropoietin (EPO), which stimulates the admeasurement of early-stage corpuscle forerunner cells. Acceleron and Celgene are accordingly developing luspatercept as allotment of a all-around collaboration. Acceleron and Celgene are enrolling Phase 3 analytic trials that are advised to appraise the assurance and ability of luspatercept in patients with myelodysplastic syndromes (the “MEDALIST” study) and in patients with beta-thalassemia (the “BELIEVE” study). For added information, amuse visit www.clinicaltrials.gov.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an chip all-around biopharmaceutical aggregation affianced primarily in the discovery, development and commercialization of avant-garde therapies for the assay of blight and anarchic diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. For added information, amuse visit www.celgene.com.

Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube.

FORWARD-LOOKING STATEMENTS

This columnist absolution contains advanced statements, which are about statements that are not actual facts. Forward-looking statements can be articular by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and agnate expressions. Forward-looking statements are based on management’s accepted plans, estimates, assumptions and projections, and allege alone as of the date they are made. We undertake no obligation to amend any advanced account in ablaze of new admonition or approaching events, except as contrarily appropriate by law. Advanced statements absorb inherent risks and uncertainties, best of which are difficult to adumbrate and are about above our control. Actual after-effects or outcomes may alter materially from those adumbrated by the advanced statements as a aftereffect of the appulse of a cardinal of factors, abounding of which are discussed in added detail in our Annual Report on Form 10-K and our added letters filed with the Securities and Exchange Commission.

Hyperlinks are provided as a accessibility and for advisory purposes only. Celgene bears no albatross for the aegis or agreeable of alien websites.

PDF) Effectiveness of Risk Evaluation and Mitigation Strategies ..
PDF) Effectiveness of Risk Evaluation and Mitigation Strategies .. | revlimid rems form

View antecedent adaptation on businesswire.com: https://www.businesswire.com/news/home/20180522005177/en/

Seven Things You Probably Didn’t Know About Revlimid Rems Form | Revlimid Rems Form – revlimid rems form
| Delightful to help the website, in this particular period I will show you concerning revlimid rems form
.

Safety - Newly Diagnosed | REVLIMID (lenalidomide) MM HCP - revlimid rems form
Safety – Newly Diagnosed | REVLIMID (lenalidomide) MM HCP – revlimid rems form | revlimid rems form
Patient Enrollment Form - revlimid rems form
Patient Enrollment Form – revlimid rems form | revlimid rems form
Dosing Schedule - Greater Than 12 Therapy | REVLIMID (lenalidomide ..
Dosing Schedule – Greater Than 12 Therapy | REVLIMID (lenalidomide .. | revlimid rems form
REVLIMID® (lenalidomide) - revlimid rems form
REVLIMID® (lenalidomide) – revlimid rems form | revlimid rems form
REVLIMID® (lenalidomide) - revlimid rems form
REVLIMID® (lenalidomide) – revlimid rems form | revlimid rems form

Gallery for Seven Things You Probably Didn’t Know About Revlimid Rems Form | Revlimid Rems Form